<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Iobenguane I-123 (diagnostic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Iobenguane I-123 (diagnostic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Iobenguane I-123 (diagnostic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12178" href="/d/html/12178.html" rel="external">see "Iobenguane I-123 (diagnostic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6860203"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AdreView</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F6815128"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F6815282"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Thyroid protective agents (eg, Lugol solution, potassium iodide), should be given at least 1 hour prior to administration (in patients at risk for accumulation in thyroid).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b2f870f5-36fc-494d-b178-35c899cbc33e">Radioimaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radioimaging:</b> IV: 10 mCi (370 MBq).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990594"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, radiation exposure may be increased in patients with severe renal impairment; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987974"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F6815343"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F6815323"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Thyroid protective agents (eg, Lugol solution, potassium iodide), should be given at least 1 hour prior to administration (in patients at risk for accumulation in thyroid).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b2f870f5-36fc-494d-b178-35c899cbc33e">Radioimaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radioimaging:</b>
<i>Pheochromocytoma and neuroblastoma:</i> IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 month to 16 years and &lt;70 kg: Dose according to body weight; see table.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;16 years and ≥70 kg: 10 mCi (370 MBq).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥16 years: Refer to adult dosing.</p>
<table border="1" data-table-id="Ioben" frame="border" rules="all">
<caption style="text-align:center;">
<b>Iobenguane I 123 Pediatric Dosing by Body Weight</b>: (Children 1 Month to 16 Years and &lt;70 kg)</caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Weight (kg)</p></th>
<th align="center">
<p style="text-indent:0em;">mCi Dose</p></th>
<th align="center">
<p style="text-indent:0em;">MBq Dose</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">3</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td>
<td align="center">
<p style="text-indent:0em;">37</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4</p></td>
<td align="center">
<p style="text-indent:0em;">1.4</p></td>
<td align="center">
<p style="text-indent:0em;">52</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="center">
<p style="text-indent:0em;">1.9</p></td>
<td align="center">
<p style="text-indent:0em;">70</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8</p></td>
<td align="center">
<p style="text-indent:0em;">2.3</p></td>
<td align="center">
<p style="text-indent:0em;">85.1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">2.7</p></td>
<td align="center">
<p style="text-indent:0em;">99.9</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">12</p></td>
<td align="center">
<p style="text-indent:0em;">3.2</p></td>
<td align="center">
<p style="text-indent:0em;">118.4</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">14</p></td>
<td align="center">
<p style="text-indent:0em;">3.6</p></td>
<td align="center">
<p style="text-indent:0em;">133.2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">16</p></td>
<td align="center">
<p style="text-indent:0em;">4</p></td>
<td align="center">
<p style="text-indent:0em;">148</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">18</p></td>
<td align="center">
<p style="text-indent:0em;">4.4</p></td>
<td align="center">
<p style="text-indent:0em;">162.8</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">4.6</p></td>
<td align="center">
<p style="text-indent:0em;">170.2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">22</p></td>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">185</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">24</p></td>
<td align="center">
<p style="text-indent:0em;">5.3</p></td>
<td align="center">
<p style="text-indent:0em;">196.1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">26</p></td>
<td align="center">
<p style="text-indent:0em;">5.6</p></td>
<td align="center">
<p style="text-indent:0em;">207.2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">28</p></td>
<td align="center">
<p style="text-indent:0em;">5.8</p></td>
<td align="center">
<p style="text-indent:0em;">214.6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">6.2</p></td>
<td align="center">
<p style="text-indent:0em;">229.4</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">32</p></td>
<td align="center">
<p style="text-indent:0em;">6.5</p></td>
<td align="center">
<p style="text-indent:0em;">240.5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">34</p></td>
<td align="center">
<p style="text-indent:0em;">6.8</p></td>
<td align="center">
<p style="text-indent:0em;">251.6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">36</p></td>
<td align="center">
<p style="text-indent:0em;">7.1</p></td>
<td align="center">
<p style="text-indent:0em;">262.7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">38</p></td>
<td align="center">
<p style="text-indent:0em;">7.3</p></td>
<td align="center">
<p style="text-indent:0em;">270.1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">7.6</p></td>
<td align="center">
<p style="text-indent:0em;">281.2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">42</p></td>
<td align="center">
<p style="text-indent:0em;">7.8</p></td>
<td align="center">
<p style="text-indent:0em;">288.6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">44</p></td>
<td align="center">
<p style="text-indent:0em;">8</p></td>
<td align="center">
<p style="text-indent:0em;">296</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">46</p></td>
<td align="center">
<p style="text-indent:0em;">8.2</p></td>
<td align="center">
<p style="text-indent:0em;">303.4</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">48</p></td>
<td align="center">
<p style="text-indent:0em;">8.5</p></td>
<td align="center">
<p style="text-indent:0em;">314.5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">8.8</p></td>
<td align="center">
<p style="text-indent:0em;">325.6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">52-54</p></td>
<td align="center">
<p style="text-indent:0em;">9</p></td>
<td align="center">
<p style="text-indent:0em;">333</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">56-58</p></td>
<td align="center">
<p style="text-indent:0em;">9.2</p></td>
<td align="center">
<p style="text-indent:0em;">340.4</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60-62</p></td>
<td align="center">
<p style="text-indent:0em;">9.6</p></td>
<td align="center">
<p style="text-indent:0em;">355.2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">64-66</p></td>
<td align="center">
<p style="text-indent:0em;">9.8</p></td>
<td align="center">
<p style="text-indent:0em;">362.6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">68</p></td>
<td align="center">
<p style="text-indent:0em;">9.9</p></td>
<td align="center">
<p style="text-indent:0em;">366.3</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113908"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, radiation exposure may be increased in patients with severe renal impairment; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51113909"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F6815141"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Local: Injection site reaction (hematoma/bruising: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Bleeding at injection site, dizziness, flushing, headache, hypersensitivity (rare), hypertension (transient), pruritus, skin rash</p></div>
<div class="block coi drugH1Div" id="F6815137"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to iobenguane, iobenguane sulfate, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F6815138"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions have been reported. Use with extreme caution in patients with iodine or iodine-contrast agent hypersensitivity (base treatment decision on assessment of benefit versus risk). Appropriate equipment and emergency medications should be available during use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use has not been evaluated for selecting therapeutic intervention or monitoring treatment response; the H/M ratio has not been used in identifying patients with a higher mortality risk. Patients were excluded from clinical studies if the risks of withdrawing interacting cardiovascular medications outweighed the potential value of imaging.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: May cause a transient increase in blood pressure (although not observed in clinical trials). Monitor blood pressure prior to administration and intermittently for 30 minutes following administration. Appropriate emergency cardiac and antihypertensive treatments should be available during use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment; safety and efficacy have not been established. Patients with severe renal impairment may have delayed elimination, therefore, increasing the radiation dose and decreasing quality of images. Not dialyzable.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sympathetic nervous system disorders: Patients with sympathetic nervous system disorders (eg, Parkinson's disease or multiple system atrophy) may have reduced cardiac uptake of iobenguane; may result in imaging errors (eg, false negatives).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Administer thyroid blocking medications (eg, potassium iodide oral solution, potassium perchlorate) at least 1 hour prior to administration (in patients at risk for accumulation in thyroid); long-term risk for thyroid neoplasia can occur from failure to block thyroid uptake of iodine 123. Thyroid blockade is not necessary for thyroidectomy patients and may not be necessary in patients with a short life-expectancy. Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 48 hours following administration to decrease radiation exposure.</p></div>
<div class="block foc drugH1Div" id="F6815353"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution:</p>
<p style="text-indent:-2em;margin-left:4em;">AdreView: Iobenguane sulfate 0.08 mg and I 123 74 MBq (2 mCi) per mL (1 ea) [contains benzyl alcohol]</p></div>
<div class="block geq drugH1Div" id="F6815126"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16321886"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (AdreView Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mci/5 mL (per each): $5,838.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F6815349"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer intravenously over 1 to 2 minutes. May flush with NS to ensure full delivery of dose. Prior to administration, a thyroid-protective agent should be administered (in patients at risk for accumulation in thyroid). Ensure adequate hydration before and after treatment; instruct patient to void frequently for 48 hours after administration to minimize bladder exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart failure:</i> Begin anterior planar chest imaging 4 hours (±10 minutes) following administration; single photon emission computed tomography (SPECT) may then be performed. Low-energy high-resolution is the recommended imaging collimator; the recommended matrix for planar images is 128 x 128; position camera to include entire heart and as much of upper chest as possible within field. Follow details within manufacturer’s labeling to determine heart to mediastinum (H/M) ratio.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pheochromocytoma and neuroblastoma:</i> Perform whole body planar scintigraphy imaging 18 to 30 hours after iobenguane I 123 administration; SPECT may be performed following planar scintigraphy (as appropriate).</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>
<div class="block admp drugH1Div" id="F52614287"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer IV over 1 to 2 minutes. May flush with NS to ensure full delivery of dose. Prior to administration, a thyroid-protective agent should be administered at least 1 hour prior to iobenguane I 123 dose (in patients at risk for accumulation in thyroid). Ensure adequate hydration before and after treatment; instruct patient to void frequently for 48 hours after administration to minimize bladder exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pheochromocytoma and neuroblastoma:</i> Perform whole body planar scintigraphy imaging 18 to 30 hours after iobenguane I 123 administration; SPECT may be performed following planar scintigraphy (as appropriate).</p></div>
<div class="block use drugH1Div" id="F6815131"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Radioimaging:</b> As an adjunct to other diagnostic tests, in the detection of primary or metastatic pheochromocytoma or neuroblastoma; scintigraphic assessment of sympathetic myocardium innervation (by measurement of heart to mediastinum [H/M] ratio of radioactivity uptake) in patients with New York Heart Association class II or class III heart failure and LVEF ≤35% (may help identify lower 1 and 2 year mortality risks, indicated by H/M ratio ≥1.6)</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Congestive heart failure patients: Use has not been established for selecting a therapeutic intervention, monitoring therapeutic response, or identifying patients with a high risk of death by using the H/M ratio.</p></div>
<div class="block mst drugH1Div" id="F15245845"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299525"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6833886"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer bupropion until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Stimulants: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer cocaine until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer guanethidine until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Labetalol: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer labetalol until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maprotiline: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer maprotiline until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer methyldopa until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer metyrosine until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer reserpine until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer St John's wort until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tapentadol: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer tapentadol until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer tramadol until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer yohimbine until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54331680"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in females of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F6815133"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Radioactive iodine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">In utero exposure to radioactive iodine may permanently impair fetal thyroid function. If use is needed during pregnancy an appropriate thyroid blocking agent is recommended to protect the mother and fetus from accumulation of I 123.</p></div>
<div class="block brc drugH1Div" id="F6815136"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iodine 123 is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends interrupting breastfeeding (express and discard milk) for 6 days after administration of iobenguane I 123 to minimize risk to the breastfed infant. Recommendations for breastfeeding following exposure vary from no interruption to up to 3 weeks following thyroid imaging (ABM [Mitchell 2018]). Interruption of breastfeeding for &gt;3 weeks following neuroblastoma imaging is also recommended (IAEA 2018). Consider evaluating radioactivity in breast milk prior to resumption of breastfeeding (ABM [Mitchell 2018]).</p></div>
<div class="block dic drugH1Div" id="F6815348"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some dietary sources of iodine include cow's milk and dairy products, fish, seaweed, eggs, chocolate, and iodized salt. </p></div>
<div class="block mop drugH1Div" id="F6815352"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">TSH, prior to therapy and every six months for life (Hamnvik 2011). Pulse and blood pressure prior to administration and intermittently for 30 minutes following; monitor for hypersensitivity reaction. Evaluate pregnancy status prior to use in females of reproductive potential.</p></div>
<div class="block pha drugH1Div" id="F6815147"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Iobenguane is structurally similar to norepinephrine and therefore is taken up and stored in adrenergic tissue such as adrenal medulla, heart, liver, lungs, salivary glands, and spleen. Iobenguane is bound to radioactive iodine in order to obtain organ and tissue images.</p></div>
<div class="block phk drugH1Div" id="F6815149"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Increased in adrenergically innervated tissues (eg, heart, salivary glands, adrenal medulla)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Has not been characterized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Iodine 123: 13.2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (70 % to 90%) within 4 days (normal renal function); feces &lt;1%</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58205589"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adreview</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adreview</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adreview</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Adreview.2015.11">
<a name="Adreview.2015.11"></a>AdreView injection (iobenguane I 123) [prescribing information]. Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iobenguane-i-123-diagnostic-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iobenguane-i-123-diagnostic-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010182">
<a name="22010182"></a>Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. <i>J Natl Cancer Inst</i>. 2011;103(21):1572-1587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iobenguane-i-123-diagnostic-drug-information/abstract-text/22010182/pubmed" id="22010182" target="_blank">22010182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iobenguane-i-123-diagnostic-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IAEA.2018">
<a name="IAEA.2018"></a>International Atomic Energy Agency. <i>IAEA Safety Standards for Protecting People and the Environment: Radiation Protection and Safety in Medical Uses of Ionizing Radiation. Specific Safety Guide No. SSG-46</i>. Vienna, Austria: IAEA; 2018. https://www​.iaea.org​/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107104">
<a name="31107104"></a>Mitchell KB, Fleming MM, Anderson PO, Giesbrandt JG; Academy of Breastfeeding Medicine. ABM Clinical Protocol #31: radiology and nuclear medicine studies in lactating women. <i>Breastfeed Med</i>. 2019;14(5):290-294. doi:10.1089/bfm.2019.29128.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iobenguane-i-123-diagnostic-drug-information/abstract-text/31107104/pubmed" id="31107104" target="_blank">31107104</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9084 Version 116.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
